<DOC>
	<DOC>NCT00421824</DOC>
	<brief_summary>Primary: - To assess complete pathological response rate of both strategies. Secondary: - Safety profile - To assess downstaging rate of both strategies. - To compare relative dose intensity of oxaliplatin and capecitabine of both strategies - To compare time to progression and overall survival of both strategies.</brief_summary>
	<brief_title>Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients with rectal adenocarcinoma. Operable tumour, confirmed by magnetic resonance of high resolution and / or endorectal echography, or, Rectal tumour at distal third, or Tumours spread more than 5 mm in perirectal fat Functional state ECOG â‰¤ 2. Good hematological, hepatic and renal function Previous pelvis radiotherapy. Previous antitumoural chemotherapy Pregnant or breastfeeding women. Childbearing women with a positive pregnancy test result at baseline. Menopausal women should not have the period for the last 12 months. History of any other neoplastic illness within the last 5 years, except for already resolved small cell skin cancer or cervix cancer. Clinically significant cardiovascular disease Confirmed peripheral neuropathy. Gastrointestinal disorders or bad absorption syndrome or noncapable to take oral medication. Blood disorders. Intercurrent noncontrolled or severe infections. Patients who have undergone major surgery, open biopsies or with significant trauma lesions within the previous 28 days. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>